Most members of the US Food and Drug Administration (FDA) advisory panel believe that the benefits of Novo Nordisk's weekly insulin icodec do not outweigh the risks. Briefing documents provided by FDA scientists showed that weekly insulin Icodec injections in a key trial had hypoglycemic problems compared to Novo Nordisk's once-daily Tresiba (insulin degludec) injections.
美国食品和药物管理局(FDA)顾问小组的大多数成员认为诺和诺德每周注射一次的胰岛素icodec的益处并未胜过风险。FDA科学家提供的简报文件显示在一项关键试验中每周注射一次的胰岛素icodec与诺和诺德每日注射一次的Tresiba(胰岛素degludec)相比存在低血糖问题。
Most members of the US Food and Drug Administration (FDA) advisory panel believe that the benefits of Novo Nordisk's weekly insulin icodec do not outweigh the risks. Briefing documents provided by FDA scientists showed that weekly insulin Icodec injection
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.